Bioluminescent assays for ADME evaluation: Dialing in CYP selectivity with luminogenic substrates

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 9, 2012, Pages 1115-1130

  Cali, James J ^a   Ma, Dongping ^a   Wood, Monika G ^a   Meisenheimer, Poncho L ^b   Klaubert, Dieter H ^b  

^a PROMEGA CORPORATION   (United States)

^b Promega Biosciences   (United States)

Author keywords

ADME; Bioluminescence; CYP induction; CYP inhibition; Cytochrome P450; Drug interaction; Drug metabolism; High throughput; Luciferase; Luciferin

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C18; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2E1; CYTOCHROME P450 2J2; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; CYTOCHROME P450 4A; CYTOCHROME P450 4A11; CYTOCHROME P450 4F; CYTOCHROME P450 4F12; CYTOCHROME P450 4F2; CYTOCHROME P450 4F3B; ETHINYLESTRADIOL; FIREFLY LUCIFERASE; FLURBIPROFEN; LUCIFERASE; LUCIFERIN; MICONAZOLE; RIFAMPICIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

ASSAY; BIOLUMINESCENCE; CHEMICAL MODIFICATION; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG METABOLISM; ENZYME INHIBITION; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; EVALUATION; HUMAN; IN VITRO STUDY; NONHUMAN; PHOTON; REVIEW; SYNTHESIS;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; LUCIFERASES; LUMINESCENT AGENTS; LUMINESCENT MEASUREMENTS; MICROSOMES, LIVER; MOLECULAR PROBES; REPRODUCIBILITY OF RESULTS; SUBSTRATE SPECIFICITY;

EID: 84865312211     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.695345     Document Type: Review

References (75)

1. Guengerich FP. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J 2006;8:E101-11
2. Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 2003;72:137-74 (Pubitemid 36930444)
3. Ekroos M, Sjogren T. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Acad Sci USA 2006;103:13682-7 (Pubitemid 44413967)
4. Guengerich PF. Cataloguing the repertoire of nature's blowtorch, P450. Chem Biol 2009;16:1215-16
5. Guengerich FP. Cytochrome P450, drugs, and diseases. Mol Intervent 2003;3:194-204
6. Yang X, Zhang B, Molony C, et al. Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Gen Res 2010;20:1020-36
7. Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 2005;4:825-33 (Pubitemid 41553963)
8. Wang MZ, Saulter JY, Usuki E, et al. CYP4F are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2, 5-bis(4-aminophenyl) furan-bis-o-methylamidoxime]. Drug Metab Dispos 2006;34:1985-94 (Pubitemid 44837759)
9. Rushmore TH, Kong TAN. Pharmacogenomiccs, regulation and signaling pathways of phase I and phase II drug metabolizing enzymes. Cur Drug Metab 2002;3:481-90 (Pubitemid 34987481)
10. Wang B, Sanchez RI, Franklin RB, et al. The involvement of CYP3A4 and CYP2C9 in the metabolism of 17alpha-ethinylestradiol. Drug Metab. Disposition 2004;32:1209-12 (Pubitemid 39410903)
11. McGinnity DF, Tucker J, Trigg S, et al. Prediction of CYP2C9-mediated drug-drug interactions: a comparison using data from recombinant enzymes and human hepatocytes. Drug Metab Dispos 2005;33:1700-7 (Pubitemid 41539969)
12. O'Reilly RA, Goulart DA, Kunze KL, et al. Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin Pharmacol Ther 1992;51:656-67
13. Segel IH. Enzyme kinetics. John Wiley and Sons New York; NY: 1975
14. Rodrigues AD. Drug-drug interactions. Marcel Dekker, Inc. New York; NY: 2002
15. Racha JK, Zhao ZS, Olejnik N, et al. Substrate dependent inhibition profiles of fourteen drugs on CYP3A4 activity measured by a high throughput LCMS/MS method with four probe drugs, midazolam, testosterone, nifedipine and terfenadine. Drug Metab Pharmacokinet 2003;18(2):128-38
16. Guidance for industry: drug interaction studies-study design, data analysis, and implications for dosing and labeling. Recommendations. U.S. Department of Health and Human Services, Food and Drug Administration. Rockville; MD: 2012
17. Nomier AA, Ruegg C, Shoemaker M, et al. Inhibition of CYP3A4 in a rapid microtiter plate assay using recombinant enzyme and in human liver microsomes using conventional substrates. Drug Metab Dispos 2001;29:748-53 (Pubitemid 32374578)
18. Li AP, Lu C, Brent JA, et al. Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem Biol Interac 1999;121:17-35 (Pubitemid 29240667)
19. Madan A, Graham RA, Carroll KM, et al. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 2003;31:421-31 (Pubitemid 36378519)
20. Li AP, Doshi U. Higher throughput human hepatocyte assays for the evaluation of time-dependent inhibition of CYP3A4. Drug Metab Lett 2011;5:183-91
21. Kaneko A, Kato M, Sekiguchi N, et al. In vitro model for the prediction of clinical CYP3A4 induction using HepaRG cells. Xenobiotica 2009;39:803-10
22. Lubberstedt M, Muller-Vieira U, Mayer M, et al. HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro. J Pharmacol Toxicol Methods 2011;63:59-68
23. Hart SN, Li Y, Nakamoto K, et al. A Comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues. Drug Metab Dispos 2010;38:988-94
24. Guguen-Guillouzoa C, Corlua A, Guillouzob A. Stem cell-derived hepatocytes and their use in toxicology. Toxicology 2010;270:3-9
25. Li AP. Evaluation of luciferin-isopropyl acetal as a CYP3A4 substrate for human hepatocytes: effects of organic solvents, cytochrome p450 (p450) inhibitors, and p450 inducers. Drug Metab Dispos 2009;37:1598-603
26. Luo G, Guenther T, Gan L-S, et al. CYP3A4 induction by xenobiotics: experimental methods and impact on drug discovery and development. Curr Drug Metab 2001;5:483-505
27. Donato TM, Jimenez N, Castell JV, et al. Fluorescence based assays for screening nine cytochrome p450 (p450) activities in intact cells expressing individual human p450 enzymes. Drug Metab Dispos 2004;32:699-706 (Pubitemid 38821870)
28. Lu C, Li AP. Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog. Chem Biol Interac 2001;134:271-81 (Pubitemid 32406149)
29. Cali JJ, Niles A, Valley MP, et al. Bioluminescent assays for ADMET. Expert Opin Drug Metab Toxicol 2008;4:103-20 (Pubitemid 351234104)
30. Cali JJ, Ma D, Sobol M, et al. Luminogenic cytochrome CYP assays. Expert Opin Drug Metab Toxicol 2006;2:629-45
31. Doshi U, Li AP. Luciferin IPA-based higher throughput human hepatocyte screening assays for CYP3A4 inhibition and induction. J Biomol Screen 2011;16:903-9
32. Meisenheimer PL, Uyeda HT, Ma D, et al. Proluciferin acetals as bioluminogenic substrates for cytochrome p450 activity and probes for cyp3A inhibition. Drug Metab Dispos 2011;39:2403-10
33. P450-Glo assay technical bulletin. Available from: http://www.promega. com/~/media/Files/Resources/Protocols/Technical%20Bulletins/101/P450% 20Glo%20Assays%20Protocol.pdf [Last accessed 22 April 2012]
34. Branchini RB, Magyar RA, Murtiashaw MH, et al. Site-directed mutagenesis of histidine 245 in firefly luciferase: model of the active site. Biochemistry 1998;37:15311-19 (Pubitemid 28515991)
35. Sobol M, Ma D, Cali JJ. Selective Cytochrome P450 4A11 Enzyme Assay Using a Novel Bioluminescent Probe Substrate. Available from: http://www.promega.com/ resources/articles/pubhub/enotes/selective-cytochrome-p450-4a11-enzyme-assay- using-a-novel-bioluminescent-probe-substrate/[Last accessed 16 January 2012]
36. Cali JJ, Ma D. A Rapid Cell Based Bioluminescent CYP1A1 Aryl Hydrocarbon Receptor Activation Assay. Available from: http://www.promega. com/resources/scientific-posters/posters/a-rapid-cell-based-bioluminscent- cyp1a1-aryl-hydrocarbon-receptor-assay-poster/[Last accessed 24 April 2012]
37. Moeller T, Ma D, Dennel S, Cali J. Comparison of novel luciferin-1A2 substrate and phenacetin for measuring CYP1A2 induction in human hepatocytes. The Toxicologist 2012:110. Available from: http://www.toxicology. org/AI/PUB/Toxicologist12.pdf [Last accessed 22 April 2012]
38. Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3-25 • Presentation of a standard paradigm for predicting drug-like properties. (Pubitemid 27046991)
39. Branchini BR, Hayward MM, Bamford S, et al. Naphthyl-and quinolylluciferin: green and red light emitting firefly luciferin analogues. Photochem Photobiol 1989;49:689-95
40. Stresser DM, Blanchard AP, Turner SD, et al. Substrate-dependent modulation of cyp3a4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 2000;28:1440-8
41. Lewis DFV, Dickins M. Baseline lipophilicity relationships in human cytochromes p450 associated with drug metabolism. Drug Metab Rev 2003;35:1-18 (Pubitemid 36249783)
42. Fan F, Wood KV. Bioluminescent assays for high-throughput screening. Assay Drug Dev Technol 2007;5:127-36 • General review of bioluminescent methods and applications. (Pubitemid 46581246)
43. Cali JJ, Ma D, Sobol MS, et al. P450-Glo™ CYP2C19 and CYP2D6 assays and screening systems. Cell Notes 2006;14:20-4
44. Vermeulen NPE. Prediction of drug metabolism: the case of cytochrome P450 2D6. Curr Top Med Chem 2003;3:1227-39
45. Krimmer HP, Drauz K, Kleemann A. Reaction of beta-mercapto alpha-amino acids with nitriles. Chem Ztg 1987;111:357-61
46. Larson B, Kelts JL, Banks P, et al. Automation and miniaturization of the bioluminescent UGT-Glo assay for screening of UDP-glucuronosyltranferase inhibition by various compounds. J Lab Automot 2011;16:38-46
47. Francisco WA, Abu-Soud HM, Baldwin TO, et al. Interaction of bacterial luciferase with aldehyde substrates and inhibitors. J Biol Chem 1993;268:24734-41 (Pubitemid 23335484)
48. Vermilion JL, Coon MJ. Highly purified detergent-solubilized NADPH-cytochrome P-450 reductase from phenobarbital-induced rat liver microsomes. Biochem Biophys Res Com 1974;60:1315-22
49. Locuson CW, Wienkers LC, Jones JP, et al. CYP2C9 protein interactions with cytochrome b5: effects on the coupling of catalysis. Drug Metab Dispos 2007;35:1174-81 (Pubitemid 46956439)
50. Sobol M, Ma D, Unch J, Cali JJ. Nonselective Cytochrome P450 Enzyme Assay Using a Novel Bioluminescent Probe Substrate that Cross-Reacts with Multiple P450 Enzymes. Available from: http://www.promega.com/resources/articles/pubhub/ enotes/nonselective-cyp450-assay-using-a-biolum-probe-substrate-that-cross- reacts-with-multiple-p450s/[Last accessed 22April 2012]
51. Wester MR, Yano JK, Schock GA, et al. The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-angstrom resolution. J Biol Chem 2004;279:35630-7 (Pubitemid 39100565)
52. Veith H, Southall N, Huang R, et al. Comprehensive characterization of cytochrome P450 isozyme selectivity across chemical libraries. Nat Biotechnol 2009;27:1050-5
53. Stevens JC. New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology. Drug Discov Today 2006;11:440-5
54. Leeder JS, Gaedigk R, Marcucci KA, et al. Variability of CYP3A7 expression in human fetal liver. Pharmacol Expert Ther 2005;314:626-35 (Pubitemid 41043843)
55. Sobol MS, Ma D, Cali JJ. Selective cytochrome p450 3A7 enzyme assay using a novel bioluminescent probe substrate. Available from: http://www.promega.com/ resources/articles/pubhub/enotes/selective-cytochrome-p450-3a7-enzyme-assay- using-a-novel-bioluminescent-probe-substrate/[Last accessed 16 January 2012]
56. Enayetallah AE, French RA, Thibodeau MS, et al. Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. Histochem Cytochem 2004;52(4):447-54 (Pubitemid 38420379)
57. Chen Y, Ferguson SS, Negishi M, et al. Induction of Human CYP2C9 by Rifampicin, Hyperforin, and Phenobarbital Is Mediated by the Pregnane X Receptor. J Pharm Expert Ther 2004;308:495-501 (Pubitemid 38134210)
58. Earley S, Patuszyn A, Walker BR. Cytochrome P-450 epoxygenase products contribute to attenuated vasoconstriction after chronic hypoxia. Am J Physiol Heart Circ Physiol 2003;285:H127-36 (Pubitemid 36736423)
59. Granville DJ, Tashakkor B, Takeuchi C, et al. Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors. Proc Nat Acad Sci USA 2003;101:1321-6 (Pubitemid 38182687)
60. Ma Q, Lu AYH. CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies. Drug Metab Dispos 2007;35:1009-16 (Pubitemid 46956419)
61. Brosen K, Skjelbo E, Rasmussen BB, et al. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;1211-14 (Pubitemid 23098317)
62. Shimada T, Fujii-Kuriyama Y. Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochrome P450 1A1 and 1B1. Cancer Sci 2004;95:1-6 (Pubitemid 38208399)
63. Shimada T, Gillam EMJ, Sutter TR, et al. Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug MEtab Dispos 1997;29:617-22 (Pubitemid 27213104)
64. Hu W, Sorrentino C, Denison MS, et al. Induction of Cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro, Mol Pharmacol. 2007;71:1475-86 (Pubitemid 47010900)
65. Zhang Z-Y, Pelletier RD, Wong YN, et al. Preferential inducibility of CYP1A1 and CYP1A2 by TCDD: differential regulation in primary hepatocytes versus transformed human cells. Biochem Biophys Res Commun 2006;341:399-407 (Pubitemid 43152120)
66. Sobol M, Ma D, Woodroofe CC, et al. Cytochrome P450 4F2 and 4F3B enzyme assays using a novel bioluminescent probe substrate. Available from: http://www.promega.com/resources/articles/pubhub/enotes/cytochrome-p450-4f2-and- 4f3b-enzyme-assays-using-a-novel-bioluminescent-probe-substrate/[Last accessed 16 January 2012]
67. Sobol M, Ma D, Cali JJ. Cytochrome P450 4F12 Enzyme Assay Using a Novel Bioluminescent Probe Substrate. Available from: http://www.promega. com/resources/articles/pubhub/enotes/cytochrome-p450-4f12-enzyme-assay-using-a- novel-bioluminescent-probe-substrate/[Last accessed 16 January 2012]
68. Kroetz DL, Zeldin DC. Cytochrome P450 pathways of arachidonic acid metabolism. Curr Opin Lipidol 2002;13:273-83 (Pubitemid 34592284)
69. Hashizume T, Imaoka S, Mise M, et al. Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharm Expert Ther 2002;300:298-304 (Pubitemid 34028540)
70. Johnson EF, Hsu M-H, Sava U, et al. Regulation of P450 4A expression by peroxisome proliferator activated receptors. Toxicology 2002;181-182:203-6 (Pubitemid 36015699)
71. Aoyama T, Hardwick JP, Imaoka S, et al. Clofibrate-inducible rat hepatic P450s IVA1 and IVA3 catalyze the omega-and (omega-1)-hydroxylation of fatty acids and the omega-hydroxylation of prostaglandins E1 and F2alpha. J Lipd Res 1990;31:1477-82 (Pubitemid 20261911)
72. Meisenheimer PL, O'Brien MA, Cali JJ. Luminogenic substrates: the basis for a new paradigm in assay design. Available from: http://www.promega.com/~/ media/Files/Resources/Cell%20Notes/cn022/Luminogenic% 20Substrates- %20The%20Basis%20for% 20a%20New%20Paradigm%20in% 20Assay%20Design.ashx [Last accessed 2 April 2012]
73. Molinspiration molecular properties calculator. Available from: http://www.molinspiration.com/cgi-bin/properties [Last accessed 17 January 2012]
74. Ma D, Sobol M, Woodroofe CC, Cali JJ. Cytochrome P450 2J2 enzyme assay using a novel bioluminescent probe substrate. Available from: http://www.promega.com/resources/articles/pubhub/enotes/cytochrome-p450-2j2- enzyme-assay-using-a-novel-bioluminescent-probe-substrate/[Last accessed 22 April 2012]
75. RCSB Protein Data Bank entry 1R90. Available from: http://www.rcsb.org/ pdb/explore/explore.do?structureId=1R9O [Last accessed 14 May 2012]